Karvouniaris Marios, Brotis Alexandros G, Tsiamalou Paraskevi, Fountas Kostas N
Intensive Care Unit, University Hospital of Larissa, Larissa, Greece.
Department of Neurosurgery, University Hospital of Larissa, Larissa, Greece.
World Neurosurg. 2018 Dec;120:e637-e650. doi: 10.1016/j.wneu.2018.08.138. Epub 2018 Aug 29.
The emergence of multidrug-resistant pathogens has resulted in difficult-to-treat ventriculitis/meningitis (VM). We used a meta-analysis to study the role of intraventricular (IVT) antibiotic administration as an adjunct (IVT plus intravenous [IV]) to the classic intravenous antimicrobial therapy (IV-only) in the management of VM in terms of infection control, functional outcome, microbial eradication, complications, cost-benefit analysis, infectious mortality, and overall mortality.
The electronic search focused on adult neurosurgical cases complicated by gram-negative VM and was limited to studies comparing IVT plus IV and IV-only. The quality of the overall body of evidence was assessed according to GRADE (Grading of Recommendations Assessment, Development, and Evaluation). The pooled estimates for each question were summarized as odds ratios (ORs) and visualized using forest plots. Every outcome was stratified according to carbapenem resistance.
Eleven studies with 348 patients fulfilled the eligibility criteria. No evidence was found for infection control, functional outcome, or complications. For the remaining items evaluated, the overall quality of the best available evidence was low. IVT plus IV treatment was statistically superior to IV-only therapy in eradication (OR, 10.06; 95% confidence interval [CI], 2.62-38.65), infectious mortality (OR, 0.1; 95% CI, 0.03-0.36), and overall mortality (OR, 0.22; 95% CI, 0.08-0.60) in the management of carbapenem-resistant pathogens only.
Combined IVT plus IV treatment did not prove superior to standard IV-only treatment in the management of VM. Nevertheless, weak evidence showed that IVT treatment might serve as an adjunct in the management of carbapenem-resistant pathogens.
多重耐药病原体的出现导致脑室炎/脑膜炎(VM)难以治疗。我们进行了一项荟萃分析,以研究脑室内(IVT)抗生素给药作为经典静脉抗菌治疗(仅静脉注射[IV])的辅助手段(IVT加静脉注射[IV])在VM治疗中在感染控制、功能结局、微生物清除、并发症、成本效益分析、感染性死亡率和总死亡率方面的作用。
电子检索聚焦于合并革兰氏阴性VM的成人神经外科病例,且仅限于比较IVT加IV和仅IV治疗的研究。根据GRADE(推荐分级评估、制定和评价)对整体证据质量进行评估。每个问题的汇总估计值总结为比值比(OR),并使用森林图进行可视化展示。每个结局根据碳青霉烯耐药性进行分层。
11项研究共348例患者符合纳入标准。在感染控制、功能结局或并发症方面未发现证据。对于评估的其余项目,现有最佳证据的整体质量较低。仅在碳青霉烯耐药病原体的治疗中,IVT加IV治疗在清除率(OR,10.06;95%置信区间[CI],2.62 - 38.65)、感染性死亡率(OR,0.1;95%CI,0.03 - 0.36)和总死亡率(OR,0.22;95%CI,0.08 - 0.60)方面在统计学上优于仅IV治疗。
在VM治疗中,IVT加IV联合治疗并未证明优于标准的仅IV治疗。然而,有微弱证据表明IVT治疗可能作为碳青霉烯耐药病原体治疗的辅助手段。